维普中文期刊产品整合服务
71篇 您的检索式:作者名="Pella"
    题名 作者 年代 出处 被引量
1Association between hepatitis B and metabolic syndrome:Current state of the art显示文摘Chronic hepatitis B(CHB)is a global health issue that increases the risk of liver cirrhosis and hepatocellular carcinoma in infected patients.Metabolic syndrome(Met S)is a disease endemic mostly to the developed countries.It is associated with high cardiovascular mortality and morbidity,diabetes mellitus as well as cancer.In this manuscript,we systematically review the published data on the relationship between Met S and CHB infection.Multiple studies have described highly variable correlations between CHB on one hand and Met S,non-alcoholic fatty liver disease and dyslipidemia on the other.No association between CHB and diabetes mellitus or atherosclerosis has been described as of now.The presence of Met S in patients infected with hepatitis B virus increases the risk of fibrosis,cirrhosis and hepatocellular carcinoma.Appropriate lifestyle,but also pharmacological interventions are needed to prevent the development of these complications.Peter Jarcuska Sylvia Drazilova Jan Fedacko Daniel Pella Martin Janicko 2016World Journal of Gastroenterology2016,22,1:8
2Molecular classifications of gastric cancers: Novel insights and possible future applications显示文摘Despite some notable advances in the systemic management of gastric cancer(GC), the prognosis of patients with advanced disease remains overall poor and their chance of cure is anecdotic. In a molecularly selected population, a median overall survival of 13.8 mo has been reached with the use of human epidermal growth factor 2(HER2) inhibitors in combination with chemotherapy, which has soon after become the standard of care for patients with HER2-overexpressing GC. Moreover, oncologists have recognized the clinical utility of conceiving cancers as a collection of different molecularlydriven entities rather than a single disease. Several molecular drivers have been identified as having crucial roles in other tumors and new molecular classifications have been recently proposed for gastric cancer as well. Not only these classifications allow the identification of different tumor subtypes with unique features, but also they serve as springboard for the development of different therapeutic strategies. Hopefully, the application of standard systemic chemotherapy, specifictargeted agents, immunotherapy or even surgery in specific cancer subgroups will help maximizing treatment outcomes and will avoid treating patients with minimal chance to respond, therefore diluting the average benefit. In this review, we aim at elucidating the aspects of GC molecular subtypes, and the possible future applications of such molecular analyses.Silvio Ken Garattini Debora Basile Monica Cattaneo Valentina Fanotto Elena Ongaro Marta Bonotto Francesca V Negri Rosa Berenato Paola Ermacora Giovanni Gerardo Cardellino Mariella Giovannoni Nicoletta Pella Mario Scartozzi Lorenzo Antonuzzo Nicola Silvestris Gianpiero Fasola Giuseppe Aprile 2017World Journal of Gastrointestinal Oncology2017,9,5:5
3Pleiotropic effects of statins in the diseases of the liver显示文摘Statins are a class of molecules that inhibit HMG Co A reductase. They are usually prescribed as a lipid lowering medication. However, there is accumulating evidence that statins have multiple secondary effects both related and unrelated to their lipid-lowering effect. This narrative review of the literature aims to provide the reader with information from clinical studies related to the effect of statin and statins' potential use in patients with liver diseases. In patients with advanced liver disease due to any etiology, statins exhibit an antifibrotic effect possibly through the prevention of hepatic sinusoidal microthrombosis. Two randomized controlled trials confirmed that statins decrease hepatic vein pressure gradient in patients with portal hypertension and improve the survival of patients after variceal bleeding. Lower rates of infections were observed in patients with cirrhosis who received statin treatment. Statins decrease the risk of hepatocellular carcinoma(HCC) in patients with advanced liver disease in general but particularly in patients with chronic hepatitis B and C. Statins in patients with chronic hepatitis C likely increase the virological response to the treatment with pegylated interferon and ribavirin and have the potential to decrease the rate of fibrosis. Finally, data from randomized controlled trials also confirmed that the addition of statin prolongs the survival of patients with advanced HCC even more than sorafenib. Statins are a very promising group of drugs especially in patients with liver disease, where therapeutic options can often be limited. Some indications, such as the prevention of re-bleeding from esophageal varices and the palliative treatment of HCC have been proven through randomized controlled trials, while additional indications still need to be confirmed through prospective studies.Martin Janicko Sylvia Drazilova Daniel Pella Jan Fedacko Peter Jarcuska 2016World Journal of Gastroenterology2016,22,27:2
4Modelling progressive hardening of shotcrete in convergence-confinement approach to tunnel design显示文摘P.P. Oreste D. Pella 1997Tunnelling and Underground Space Technology incorporating Trenchless Technology Research1997,,:1
5Mechanisms of acute myocardial infarction study (MAMIS) 显示文摘Singh RB Pella D Neki NS 2004Biomed Pharmacother2004,58,1:1
6Germ-cell deficient (gcd), an insertional mutation manifested as infertility in transgenic mice显示文摘Pellas TC Ramachandran B Duncan M 1991Proc Natl Acad Sci USA1991,88,19:1
7Prevalence and risk factors for prehypertension and hypertension in five Indian cities 显示文摘Singh RB Fedacko J Pella D 2011Acta Cardiol2011,66,1:1
8Referents to Scientific Literary 显示文摘Pella Metal 1996Jottrrtal of Research in Science Tenching1996,,4:1
9Bullying behaviors a-mong US youth: prevalence and association with psychosocial ad-justment 显示文摘Anselm TR Overpeck M Pella RS 2001J Am Med Assoc2001,285,16:1
10Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study显示文摘Luisa Foltran Giuseppe Aprile Federica Edith Pisa Paola Ermacora Nicoletta Pella Emiliana Iaiza Elena Poletto Stefania Eufemia Lutrino Micol Mazzer Mariella Giovannoni Giovanni Gerardo Cardellino Fabio Puglisi Gianpiero Fasola 2014Supportive Care in Cancer2014,,9:1
11Blink and you live:the locked-in syndrome显示文摘Bruno MA Pellas F Schnakers C 2008Revue Neurologique (Paris)2008,164,:1
12prevalence and risk fac- tors for prehypertension and hypertension in five Indian cities 显示文摘Singh RB Fedacko J Pella D 2011Acta Cardiol2011,66,1:1
13The locked-in syndrome:What is it like to be conscious but paralyzed and voiceless?显示文摘Laureys S Pellas F Van EP 2005Prog Bra Res2005,150,:1
14Coenzyme Q10 in heart and brain diseases显示文摘Fedacko J Pella D Fedackova P 2011Open Nutra J2011,4,:1
15Large‐scale relationships between basin and riparian land cover and the ecological status of European rivers显示文摘JEAN‐GABRIELWASSON BERTRANDVILLENEUVE ARVOIITAL JOHNMURRAY‐BLIGH MARCELADOBIASOVA STANISLAVABACIKOVA HENNTIMM HERVéPELLA NICOLASMENGIN ANDRéCHANDESRIS 2010Freshwater Biology2010,,7:1
16Germ-cell deficient(gcd),an insertional mutantion manifested as infertility in transgenic mice显示文摘Pellas T C Ramachandran B Duncan M 1991Proc Natl Acad Sci USA1991,88,:1
17Targeting accuracy in real-time tumor tracking via external surrogates : a comparative study显示文摘Torshabi A Pella A Riboldi M 2010Technology in Cancer Research & Treatment2010,9,6:1
18Germ-cell deficient (gcd), an insertional mutation manifested as infertility in transgenic mice 显示文摘Pellas TC Ramachandran B Duncan M 1991Proc Natl Acad Sci USA1991,88,19:1
19Real-time tumor tracking with an artificial neural networks-based method: a feasibility study显示文摘Seregni M Pella A Riboldi M 2013Phys Med2013,29,1:1
20Targeting accuracy in real-time tumor tracking via extemal surrogates: a comparative study显示文摘Torshabi AE Pella A Riboldi M 2010Teclm- ol Cancer Res Treat2010,9,6:1
返回顶部 每页显示:
共4页 首页 上一页 第1页 下一页 末页 /4 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费